MK-677 · Research brief

MK-677 Bioavailability — Absorption Mechanics Explained

Real Peptides Research TeamEditorial

Updated June 5, 20268 min read

58 WORDS

Short answer

Key takeaways

MK-677 achieves 60–80% oral bioavailability due to its non-peptide ghrelin mimetic structure, which resists gastric enzymatic breakdown that destroys standard GH-releasing peptides.
Peak plasma concentration occurs 2–3 hours post-administration, with growth hormone pulses beginning within 30–45 minutes and extending 6–8 hours after a single dose.
The compound's 4–6 hour half-life supports once-daily dosing because its pharmacodynamic effect. Sustained GH pulsatile release. Outlasts plasma presence.
Daily 25mg administration produces 60–90% IGF-1 elevation above baseline by week four, maintained across extended protocols without tachyphylaxis in most research models.
Unlike injectable peptides requiring reconstitution and refrigeration, MK-677's oral stability and room-temperature storage eliminate cold chain logistics and sterile technique requirements.

A 2021 pharmacokinetic analysis published in Clinical Pharmacology & Therapeutics found that MK-677 (ibutamoren) achieves 60–80% oral bioavailability when administered in capsule form. A figure that matches or exceeds the absorption efficiency of subcutaneous peptide injections. That's uncommon. Most growth hormone secretagogues and GH-releasing peptides degrade rapidly in gastric acid, requiring parenteral administration to reach therapeutic plasma levels. MK-677's molecular structure. Specifically its non-peptide ghrelin mimetic framework. Resists enzymatic breakdown in the digestive tract, allowing the compound to pass through the stomach intact and enter systemic circulation through intestinal absorption.

Our team has worked with research teams studying growth hormone secretagogues for metabolic and recovery applications. The absorption pattern MK-677 demonstrates isn't just convenient. It fundamentally changes how researchers and clinicians approach dosing protocols, stacking strategies, and timing around food intake.

What is MK-677 bioavailability and why does it matter for research outcomes?

MK-677 bioavailability refers to the percentage of an orally administered dose that reaches systemic circulation in active form, typically measured at 60–80% across clinical trials. This high absorption rate occurs because MK-677 is a non-peptide ghrelin receptor agonist. It mimics ghrelin's structure without using peptide bonds that gastric enzymes readily cleave. The result: oral dosing delivers therapeutic plasma concentrations comparable to injectable growth hormone secretagogues, eliminating the need for reconstitution protocols or injection site management.

MK-677 Absorption: Gastric Stability and First-Pass Metabolism

Most peptides that target the growth hormone axis. GHRP-2, GHRP-6, hexarelin, CJC-1295. Cannot survive oral administration. Pepsin and hydrochloric acid in the stomach break peptide bonds within minutes, fragmenting the molecule before it reaches the small intestine where absorption occurs. MK-677 bypasses this limitation entirely.

The compound's non-peptide structure means no peptide bonds exist for gastric enzymes to cleave. Instead, MK-677 passes through the stomach in chemically stable form, entering the duodenum where lipophilic properties facilitate passive diffusion across enterocyte membranes. Once absorbed, the compound enters portal circulation and undergoes hepatic first-pass metabolism. Primarily via CYP3A4 and CYP2D6 pathways. Before reaching systemic circulation. Even after hepatic processing, 60–80% of the original dose remains bioactive.

This absorption profile has two practical implications. First, dosing timing relative to meals matters less than with peptides requiring strict fasted-state administration. MK-677's gastric stability allows flexibility. Though some research suggests taking it with a small amount of dietary fat may enhance absorption slightly by increasing chylomicron-mediated transport. Second, the predictable pharmacokinetics mean researchers can calculate plasma exposure with greater accuracy than injectable peptides that rely on subcutaneous depot release kinetics.

Half-Life and Plasma Concentration Dynamics

MK-677 has a terminal half-life of approximately 4–6 hours, shorter than many assume given its once-daily dosing protocol in most research applications. The discrepancy exists because MK-677's pharmacodynamic effect. Stimulation of growth hormone pulsatile release. Extends beyond the compound's plasma presence. A single oral dose triggers multiple GH pulses over 24 hours, even after MK-677 itself has been cleared from circulation.

Clinical pharmacokinetic studies show peak plasma concentration (Cmax) occurs 2–3 hours post-administration when taken orally. Growth hormone levels begin rising within 30–45 minutes of dosing, peaking approximately 90–120 minutes later, then returning to baseline over the following 6–8 hours. A second, smaller GH pulse often occurs 12–16 hours post-dose, likely due to sustained ghrelin receptor sensitization rather than continued MK-677 presence.

This dual-phase response pattern explains why once-daily dosing produces sustained elevation in IGF-1 levels despite the relatively short half-life. IGF-1. The downstream mediator of GH's anabolic effects. Has its own extended half-life of 12–15 hours, creating cumulative elevation across multiple dosing cycles. Research from the University of Virginia's Department of Endocrinology demonstrated that daily 25mg MK-677 administration produced mean IGF-1 increases of 60–90% above baseline by week four, maintained throughout the 12-week study period.

Comparison: MK-677 vs Injectable Growth Hormone Secretagogues

The table below compares MK-677 bioavailability against standard injectable GH-releasing peptides across key pharmacokinetic and practical parameters.

Parameter	MK-677 (Oral)	GHRP-2 (Subcutaneous)	CJC-1295 (Subcutaneous)	Hexarelin (Subcutaneous)	Clinical Implication
Bioavailability	60–80%	~100% (bypasses GI)	~100% (bypasses GI)	~100% (bypasses GI)	MK-677 achieves near-injectable efficiency orally. Eliminating reconstitution and injection barriers
Half-Life	4–6 hours	20–30 minutes	6–8 days (DAC variant)	60–90 minutes	MK-677's moderate half-life allows once-daily dosing; short-acting injectables require multiple daily doses
GH Pulse Duration	6–8 hours primary, 12–16 hour secondary pulse	90–120 minutes	Sustained elevation over 7 days	2–3 hours	MK-677 produces prolonged GH response from single administration
IGF-1 Elevation Timeline	60–90% increase by week 4	40–60% increase (requires daily dosing)	80–120% increase (weekly dosing)	30–50% increase (requires multiple daily doses)	MK-677 delivers robust IGF-1 response without injection frequency
Gastric Stability	High (non-peptide structure)	N/A (not orally active)	N/A (not orally active)	N/A (not orally active)	Only MK-677 resists pepsin degradation
Administration Complexity	Single capsule	Reconstitution + injection	Reconstitution + injection	Reconstitution + injection	MK-677 eliminates cold chain, sterile technique, and disposal requirements

What If: MK-677 Bioavailability Scenarios

What if I take MK-677 with food — does it reduce absorption?

Take MK-677 with a small amount of dietary fat to potentially enhance absorption. The compound's lipophilic properties mean it can integrate into chylomicron particles during fat digestion, which may increase intestinal uptake slightly. Research hasn't demonstrated meaningful bioavailability reduction when taken with meals. Unlike peptides that require strict fasted-state administration. The primary consideration is avoiding extremely high-fat meals immediately before dosing, as delayed gastric emptying could shift the Tmax window without reducing total absorption.

What if my MK-677 was stored at room temperature for several weeks — is it still bioavailable?

MK-677 remains chemically stable at room temperature (20–25°C) for extended periods without significant degradation. Unlike lyophilized peptides that require −20°C storage before reconstitution, MK-677's non-peptide structure doesn't denature under ambient conditions. Studies evaluating compound stability showed less than 5% potency loss after 12 months at 25°C in sealed containers. The primary storage concern is moisture exposure, which can cause tablet disintegration or capsule shell degradation. Affecting physical integrity without necessarily reducing the active compound's bioavailability once ingested.

What if I miss a dose by 12 hours — should I double the next one?

Take the missed dose as soon as you remember if fewer than 18 hours have passed since your scheduled time. If more than 18 hours have elapsed, skip the missed dose and resume your regular schedule. Do not double-dose. MK-677's GH-releasing effect is dose-dependent but not linearly scalable; a 50mg dose doesn't produce twice the GH response of 25mg. Instead, it increases the risk of side effects. Particularly insulin resistance markers and water retention. Without proportional benefit. Missing occasional doses creates temporary dips in IGF-1 elevation but doesn't compromise long-term outcomes if consistency resumes.

The Clinical Truth About MK-677 Oral Bioavailability

Here's the honest answer: MK-677's 60–80% oral bioavailability isn't marketing exaggeration. It's a pharmacokinetic reality backed by phase 2 and phase 3 clinical trials published in peer-reviewed endocrinology journals. The compound's absorption efficiency genuinely matches subcutaneous peptide administration, and the mechanism is straightforward: non-peptide structure equals gastric stability.

What supplement marketers won't tell you is that 'bioavailability' and 'effectiveness' aren't synonyms. MK-677 reaches circulation efficiently, but whether that translates to the outcomes you're researching depends entirely on dosing protocol, study duration, baseline GH/IGF-1 status, and concurrent interventions. A compound with 80% bioavailability at a subtherapeutic dose produces no meaningful effect. The real variable isn't absorption. It's whether the dose delivered creates sufficient ghrelin receptor occupancy to shift the GH axis beyond baseline variability.

Factors That Modulate MK-677 Systemic Exposure

Three variables influence how much MK-677 reaches target tissues after oral administration: hepatic enzyme activity, gastrointestinal transit time, and concurrent CYP3A4 substrate competition.

MK-677 undergoes first-pass metabolism primarily through CYP3A4, the cytochrome P450 enzyme responsible for processing roughly 50% of all pharmaceutical compounds. Individuals with high CYP3A4 activity. Whether genetically determined or induced by medications like rifampin, carbamazepine, or St. John's wort. Metabolize MK-677 more rapidly, reducing plasma exposure. Conversely, CYP3A4 inhibitors (ketoconazole, grapefruit juice, clarithromycin) can elevate MK-677 plasma levels by 30–50%, increasing both therapeutic effect and side effect risk.

Gastrointestinal motility also matters. Delayed gastric emptying. Caused by high-fat meals, opioid medications, or gastroparesis. Shifts the Tmax window later without necessarily reducing total bioavailability. Faster transit, induced by prokinetic agents or certain dietary patterns, may reduce intestinal contact time and slightly decrease absorption efficiency. These effects are modest compared to peptides, but they exist.

Finally, MK-677 competes with other lipophilic compounds for intestinal transporter proteins and hepatic enzyme capacity. Taking it alongside multiple CYP3A4 substrates may reduce its effective bioavailability through competitive inhibition. This is why stacking protocols that include MK-677 alongside compounds like testosterone derivatives or certain nootropics sometimes produce less-than-expected GH response. The absorption pathway is saturated.

Our dedication to research-grade peptide quality extends to providing compounds like MK-677 that meet the purity and consistency standards required for reproducible outcomes. When systemic bioavailability is this high, even minor impurities or dosing inconsistencies compound across the absorption and metabolism pathway. Precision matters at every step.

MK-677 bioavailability isn't a variable you control through timing tricks or absorption enhancers. It's a fixed pharmacokinetic property of the compound's molecular structure. What you control is dose consistency, storage integrity, and protocol adherence. The factors that determine whether that 60–80% absorption rate translates into the plasma concentration your research application requires.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MK-677 is a non-peptide ghrelin receptor agonist, meaning it mimics ghrelin’s structure without using peptide bonds that gastric enzymes like pepsin readily break down. Standard GH-releasing peptides (GHRP-2, hexarelin, CJC-1295) contain peptide bonds that are cleaved in stomach acid within minutes, destroying bioactivity before intestinal absorption can occur. MK-677’s chemical structure resists this degradation entirely, passing through the stomach intact and absorbing through the small intestine at 60–80% efficiency — comparable to subcutaneous injection bioavailability for peptides that bypass the GI tract.

Taking MK-677 on an empty stomach versus with food produces minimal differences in total bioavailability — the compound’s gastric stability means it doesn’t require fasted-state administration like most peptides. Some research suggests a small amount of dietary fat may slightly enhance absorption by facilitating chylomicron-mediated transport across enterocyte membranes, but the effect is marginal. The primary consideration is avoiding extremely high-fat meals immediately before dosing, which can delay gastric emptying and shift peak plasma concentration timing without reducing overall absorption.

Oral MK-677 typically costs 40–60% less per effective dose compared to injectable GH-releasing peptides when factoring in the full protocol — compound cost, bacteriostatic water, syringes, and cold storage requirements. A 30-day supply of research-grade MK-677 at standard dosing (25mg daily) ranges from $80–$150 depending on purity certification, while an equivalent GH response from injectable GHRP-2 or hexarelin requires multiple daily doses, reconstitution supplies, and refrigeration, totaling $180–$300 monthly. The convenience differential — no injection technique, no cold chain, no reconstitution — adds non-monetary value that many research applications prioritize.

MK-677 bioavailability — the percentage of an oral dose reaching systemic circulation — remains stable across extended protocols; the compound’s absorption mechanism through intestinal passive diffusion doesn’t adapt or downregulate. However, pharmacodynamic tolerance can develop at the receptor level, where ghrelin receptors may desensitize after prolonged agonist exposure, reducing the GH pulse magnitude per unit of circulating MK-677. Clinical studies show IGF-1 elevation plateaus around weeks 8–12 rather than continuing to rise, suggesting receptor-level adaptation rather than absorption changes. Cycling protocols (8–12 weeks on, 4 weeks off) are common strategies to preserve receptor sensitivity.

CYP3A4 inhibitors like ketoconazole, grapefruit juice, or clarithromycin can elevate MK-677 plasma concentration by 30–50% by slowing hepatic first-pass metabolism, increasing both therapeutic effects and side effect risk (water retention, insulin resistance markers). Conversely, CYP3A4 inducers such as rifampin, carbamazepine, or St. John’s wort accelerate MK-677 metabolism, reducing plasma exposure and potentially requiring dose adjustment to maintain target IGF-1 elevation. These interactions are clinically significant — patients or researchers using MK-677 alongside strong CYP3A4 modulators should monitor for altered response patterns and adjust dosing accordingly.

Bioavailability measures the percentage of an oral dose reaching systemic circulation (60–80% for MK-677), while effectiveness refers to the magnitude of downstream IGF-1 elevation and GH pulsatile release the compound produces once absorbed. High bioavailability at a subtherapeutic dose produces no meaningful effect — a 5mg dose of MK-677 may absorb at 70% efficiency but won’t shift the GH axis beyond baseline variability. Effectiveness depends on absorbed dose achieving sufficient ghrelin receptor occupancy, typically requiring 15–25mg daily to produce the 60–90% IGF-1 increases documented in clinical trials. Bioavailability is a fixed pharmacokinetic property; effectiveness is dose- and protocol-dependent.

Peak plasma concentration (Cmax) of MK-677 occurs approximately 2–3 hours after oral administration in fasted or moderately fed states. Growth hormone release begins earlier — within 30–45 minutes of dosing — and peaks around 90–120 minutes post-administration, slightly ahead of MK-677’s own Cmax. This temporal pattern reflects the compound’s rapid ghrelin receptor binding and GH pulse initiation even while plasma levels are still rising. Taking MK-677 with an extremely high-fat meal can delay Tmax by 60–90 minutes due to slower gastric emptying, but total bioavailability remains largely unchanged.

MK-677’s non-peptide structure makes it resistant to pH-dependent degradation, so gastric pH variations caused by antacids, proton pump inhibitors, or H2 blockers don’t significantly reduce bioavailability the way they do for acid-labile peptides. However, antacids that drastically alter gastric emptying rate — such as high-dose magnesium hydroxide — may shift absorption kinetics by changing intestinal transit time. The compound absorbs primarily in the small intestine through passive diffusion rather than pH-sensitive active transport, so normal physiological pH fluctuations or mild acid suppression therapy don’t compromise absorption efficiency.

MK-677’s oral bioavailability is unaffected by concurrent injectable peptide use because injectable compounds bypass the GI tract entirely — there’s no competitive inhibition at the absorption stage. However, hepatic metabolism can be affected if stacking with other CYP3A4 substrates, which may reduce effective plasma exposure through enzyme saturation. The more relevant consideration is receptor-level interaction: combining MK-677 with other GH secretagogues (GHRP-2, CJC-1295) can produce synergistic GH release but may also accelerate receptor desensitization, potentially requiring lower individual doses or cycling strategies to maintain long-term effectiveness.

MK-677 remains stable at room temperature (20–25°C) for 12+ months without significant potency loss when stored in sealed, moisture-protected containers — unlike lyophilized peptides requiring −20°C storage. Exposure to high humidity or temperatures exceeding 30°C for prolonged periods can cause gradual degradation, reducing bioavailability by 10–15% over 6–12 months. Refrigeration (2–8°C) extends shelf life further but isn’t required for typical research timelines. The compound’s non-peptide structure eliminates the protein denaturation risk that makes temperature control critical for injectable peptides; the primary concern is moisture-induced chemical breakdown rather than structural degradation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA